Literature DB >> 28785543

Should Age at Diagnosis Be Included as an Additional Variable in the Risk of Recurrence Classification System in Patients with Differentiated Thyroid Cancer.

Fabián Pitoia1, Fernando Jerkovich1, Anabella Smulever1, Gabriela Brenta2, Fernanda Bueno1, Graciela Cross1.   

Abstract

OBJECTIVE: To evaluate the influence of age at diagnosis on the frequency of structural incomplete response (SIR) according to the modified risk of recurrence (RR) staging system from the American Thyroid Association guidelines. PATIENTS AND METHODS: We performed a retrospective analysis of 268 patients with differentiated thyroid cancer (DTC) followed up for at least 3 years after initial treatment (total thyroidectomy and remnant ablation). The median follow-up in the whole cohort was 74.3 months (range: 36.1-317.9) and the median age at diagnosis was 45.9 years (range: 18-87). The association between age at diagnosis and the initial and final response to treatment was assessed with analysis of variance (ANOVA). Patients were also divided into several groups considering age younger and older than 40, 50, and 60 years.
RESULTS: Age at diagnosis was not associated with either an initial or final statistically significant different SIR to treatment (p = 0.14 and p = 0.58, respectively). Additionally, we did not find any statistically significant differences when the percentages of SIR considering the classification of RR were compared between different groups of patients by using several age cutoffs.
CONCLUSIONS: When patients are correctly risk stratified, it seems that age at diagnosis is not involved in the frequency of having a SIR at the initial evaluation or at the final follow-up, so it should not be included as an additional variable to be considered in the RR classifications.

Entities:  

Keywords:  Age; Differentiated thyroid cancer; Response to treatment; Risk of recurrence; Structural incomplete response

Year:  2017        PMID: 28785543      PMCID: PMC5527172          DOI: 10.1159/000453450

Source DB:  PubMed          Journal:  Eur Thyroid J        ISSN: 2235-0640


  29 in total

1.  Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.

Authors:  R Michael Tuttle; Hernan Tala; Jatin Shah; Rebecca Leboeuf; Ronald Ghossein; Mithat Gonen; Matvey Brokhin; Gal Omry; James A Fagin; Ashok Shaha
Journal:  Thyroid       Date:  2010-10-29       Impact factor: 6.568

2.  Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients.

Authors:  Maria Grazia Castagna; Fabio Maino; Claudia Cipri; Valentina Belardini; Alexandra Theodoropoulou; Gabriele Cevenini; Furio Pacini
Journal:  Eur J Endocrinol       Date:  2011-07-12       Impact factor: 6.664

3.  Optimal management of a biochemical incomplete response to therapy in differentiated thyroid cancer: aggressive treatment or cautious observation?

Authors:  R Michael Tuttle
Journal:  Endocrine       Date:  2014-03-11       Impact factor: 3.633

4.  Population-based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer.

Authors:  Limin Yang; Weidong Shen; Naoko Sakamoto
Journal:  J Clin Oncol       Date:  2012-12-26       Impact factor: 44.544

5.  Implementing the Modified 2009 American Thyroid Association Risk Stratification System in Thyroid Cancer Patients with Low and Intermediate Risk of Recurrence.

Authors:  Fabián Pitoia; Fernando Jerkovich; Carolina Urciuoli; Angélica Schmidt; Erika Abelleira; Fernanda Bueno; Graciela Cross; R Michael Tuttle
Journal:  Thyroid       Date:  2015-08-06       Impact factor: 6.568

6.  Reevaluating the prognostic significance of age in differentiated thyroid cancer.

Authors:  Samuel L Oyer; Valerie A Smith; Eric J Lentsch
Journal:  Otolaryngol Head Neck Surg       Date:  2012-03-30       Impact factor: 3.497

Review 7.  Staging systems for papillary thyroid carcinoma: a review and comparison.

Authors:  Brian Hung-Hin Lang; Chung-Yau Lo; Wai-Fan Chan; King-Yin Lam; Koon-Yat Wan
Journal:  Ann Surg       Date:  2007-03       Impact factor: 12.969

8.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

9.  Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma.

Authors:  Steven Orlov; David Orlov; Michael Shaytzag; Mark Dowar; Vafa Tabatabaie; Philip Dwek; Jonathan Yip; Cindy Hu; Jeremy L Freeman; Paul G Walfish
Journal:  Head Neck       Date:  2009-06       Impact factor: 3.147

10.  Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems.

Authors:  Fabián Pitoia; Fernanda Bueno; Carolina Urciuoli; Erika Abelleira; Graciela Cross; R Michael Tuttle
Journal:  Thyroid       Date:  2013-07-25       Impact factor: 6.568

View more
  6 in total

1.  Treatment-Free Survival in Patients With Differentiated Thyroid Cancer.

Authors:  Mousumi Banerjee; David Reyes-Gastelum; Megan R Haymart
Journal:  J Clin Endocrinol Metab       Date:  2018-07-01       Impact factor: 5.958

2.  Incomplete response to therapy in intermediate- and high-risk thyroid cancer.

Authors:  Ali S Alzahrani; Noha Mukhtar
Journal:  Endocrine       Date:  2022-09-08       Impact factor: 3.925

3.  Disease-free Survival of Patients with Differentiated Thyroid Cancer: A Study from a Tertiary Center in Oman.

Authors:  Fathimabeebi P Kunjumohamed; Abdulhakeem Al Rawahi; Noor B Al Busaidi; Hilal N Al Musalhi
Journal:  Oman Med J       Date:  2021-03-31

4.  Exosomal miR-130a-3p promotes the progression of differentiated thyroid cancer by targeting insulin-like growth factor 1.

Authors:  Guang Yin; Wencheng Kong; Sixin Zheng; Yuqiang Shan; Jian Zhang; Rongchao Ying; Hao Wu
Journal:  Oncol Lett       Date:  2021-02-12       Impact factor: 2.967

5.  Clinic-pathologic Features and Prognostic Analysis of Thyroid Cancer in the Older Adult: A SEER Based Study.

Authors:  Li-Ye Shi; Jiang Liu; Lu-Jiao Yu; Yi-Ming Lei; Sean X Leng; Hai-Yan Zhang
Journal:  J Cancer       Date:  2018-07-01       Impact factor: 4.207

6.  Course and Predictive Factors of Incomplete Response to Therapy in Low- and Intermediate-Risk Thyroid Cancer.

Authors:  Ali S Alzahrani; Yosra Moria; Noha Mukhtar; Hadeel Aljamei; Sedra Mazi; Lina Albalawi; Abeer Aljomaiah
Journal:  J Endocr Soc       Date:  2020-11-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.